Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial

Wakabayashi, Toshihiko and Iuchi, Toshihiko and Tsuyuguchi, Naohiro and Nishikawa, Ryo and Arakawa, Yoshiki and Sasayama, Takashi and Miyake, Keisuke and Nariai, Tadashi and Narita, Yoshitaka and Hashimoto, Naoya and Okuda, Osamu and Matsuda, Hiroshi and Kubota, Kazuo and Ito, Kimiteru and Nakazato, Yoichi and Kubomura, Kan (2017) Diagnostic Performance and Safety of Positron Emission Tomography Using 18F-Fluciclovine in Patients with Clinically Suspected High- or Low-grade Gliomas: A Multicenter Phase IIb Trial. Asia Oceania Journal of Nuclear Medicine and Biology, 5 (1). pp. 10-21.

[img]
Preview
Text
AOJNMB_Volume 5_Issue 1_Pages 10-21.pdf

Download (1MB) | Preview
Official URL: http://aojnmb.mums.ac.ir/article_7869.html

Abstract

Objective(s): The study objective was to assess the diagnostic performance of positron emission tomography (PET) for gliomas using the novel tracer 18F-fluciclovine (anti-18FFACBC) and to evaluate the safety of this tracer in patients with clinically suspected gliomas.Methods: Anti-18FFACBC was administered to 40 patients with clinically suspected high- or low-grade gliomas, followed by PET imaging. T1-weighted, contrast-enhanced T1-weighted, and fluid-attenuated inversion recovery (or T2-weighted) magnetic resonance imaging (MRI) scans were obtained to plan for the tissue collection. Tissues were collected from either �areas visualized using anti-18FFACBC PET imaging but not using contrast-enhanced T1-weighted imaging� or �areas visualized using both anti-18FFACBC-PET imaging and contrast-enhanced T1-weighted imaging� and were histopathologically examined to assess the diagnostic accuracy of anti-18FFACBC-PET for gliomas.Results: The positive predictive value of anti-18FFACBC-PET imaging for glioma in areas visualized using anti-18FFACBC-PET imaging, but not visualized using contrast-enhanced T1- weighted images, was 100.0% (26/26), and the value in areas visualized using both contrastenhanced T1-weighted imaging and anti- 18FFACBC-PET imaging was 87.5% (7/8). Twelve adverse events occurred in 7 (17.5%) of the 40 patients who received anti-18FFACBC. Five events in five patients were considered to be adverse drug reactions; however, none of the events were serious, and all except one resolved spontaneously without treatment.Conclusion: This Phase IIb trial showed that anti-18FFACBC-PET imaging was effective for the detection of gliomas in areas not visualized using contrast-enhanced T1-weighted MRI and the tracer was well tolerated.

Item Type: Article
Subjects: WN Radiology . Diagnostic Imaging
Divisions: Journals > Asia Oceania J Nuclear Medicine & Biology
Depositing User: AOJNMB AOJNMB
Date Deposited: 19 Sep 2017 12:18
Last Modified: 19 Sep 2017 12:18
URI: http://eprints.mums.ac.ir/id/eprint/961

Actions (login required)

View Item View Item